muraglitazar has been researched along with phenylbutazone in 1 studies
| Studies (muraglitazar) | Trials (muraglitazar) | Recent Studies (post-2010) (muraglitazar) | Studies (phenylbutazone) | Trials (phenylbutazone) | Recent Studies (post-2010) (phenylbutazone) |
|---|---|---|---|---|---|
| 85 | 10 | 25 | 6,291 | 317 | 125 |
| Protein | Taxonomy | muraglitazar (IC50) | phenylbutazone (IC50) |
|---|---|---|---|
| fMet-Leu-Phe receptor | Homo sapiens (human) | 5.3 | |
| Cyclooxygenase-2 | Canis lupus familiaris (dog) | 3.79 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Califf, RM; Demets, D; George, JT; Gerstein, HC; Granger, C; Green, JB; Hobbs, T; Holman, RR; Lawson, FC; Leiter, LA; McGuire, DK; McMurray, J; Pagidipati, NJ; Pfeffer, MA; Reusch, J; Riesmeyer, JS; Roe, MT; Rosenberg, Y; Sharma, A; Temple, R; Wiviott, S | 1 |
1 other study(ies) available for muraglitazar and phenylbutazone
| Article | Year |
|---|---|
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucose; Glycated Hemoglobin; Glycine; Government Regulation; Humans; Hypoglycemic Agents; Oxazoles; Phenylbutazone; Practice Guidelines as Topic; Risk; Rosiglitazone; Tolbutamide; United States; United States Food and Drug Administration | 2020 |